Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program by Carolyn Helms | Sep 9, 2021 | Portfolio News
LEXEO Therapeutics Closes $100 Million Series B Financing by Carolyn Helms | Sep 9, 2021 | Portfolio News
Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia by Carolyn Helms | Sep 8, 2021 | Portfolio News
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma by Carolyn Helms | Aug 30, 2021 | Portfolio News
RxSight Announces Appointments to its Board of Directors by Carolyn Helms | Aug 10, 2021 | Portfolio News
